(CercleFinance.com) – The European Medicines Agency (EMA) announces that it has started evaluating the conditional marketing authorization application for Pfizer’s Paxlovid, an oral antiviral drug that could be used to treat mild forms to moderate of Covid in adults and adolescents from 12 years of age at high risk of progression to a more severe form.
The EMA will assess the benefits and risks of Paxlovid within a short timeframe and may issue an opinion in a few weeks, in particular thanks to the work already carried out by the Committee for Medicinal Products for Human Use (CHMP).
If the additional data submitted with the Marketing Authorization Application shows that the benefits of Paxlovid outweigh its risks, then the EMA will liaise with the European Commission in order to expedite the time to market. conditional product in all EU and EEA member states.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
